Carebot s.r.o.
5
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Multi-Reader Retrospective Study Examining Carebot AI CXR 2.0.21-v2.01 Implementation in Everyday Radiology Clinical Practice
Role: lead
Evaluation of Carebot AI MMG Medical Device for Breast Lesion Detection and Density Assessment
Role: lead
Enhancing Diagnostic Accuracy in Fracture Identification on Musculoskeletal Radiographs Using Deep Learning
Role: lead
Diagnostic Accuracy of Carebot AI MMG in Mammography Screening: Multicenter MRMC Study
Role: lead
Retrospective Study of Carebot AI CXR Performance in Preclinical Practice
Role: lead
All 5 trials loaded